Intriguingly, our findings indicate that HTOL is able to antagonize the IRF4 pathway, leading to a significant down-regulation of IRF4 and its validated targets, which likely contributes to its anti-MM activity in our experimental models. Here, IRF4 is linked to Miyoshi myopathy.